Skip to main content

Mepsevii FDA Approval History

FDA Approved: Yes (First approved November 15, 2017)
Brand name: Mepsevii
Generic name: vestronidase alfa
Dosage form: Injection
Company: Ultragenyx Pharmaceutical Inc.
Treatment for: Mucopolysaccharidosis Type VII

Mepsevii (vestronidase alfa) is a recombinant human lysosomal beta glucuronidase indicated for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome).

Development timeline for Mepsevii

Nov 15, 2017Approval FDA Approves Mepsevii (vestronidase alfa) for Mucopolysaccharidosis Type VII

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.